Literature DB >> 23111709

Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit.

Cristina Vega-Cabrera1, Gloria Del Peso, Auxiliadora Bajo, M-Luz Picazo, Begoña Rivas-Becerra, Ana-Lidia Benitez, Jorge Martínez Ara, Teresa Olea, Rafael Selgas.   

Abstract

A 27-year-old man was hospitalized for acute kidney injury associated with antiglomerular basement membrane antibodies (anti-GBM). He underwent immunosuppression and plasma exchange therapy, without recovery of renal function. Later on, he was again admitted to the hospital with seizures. Evidence of microangiopathic hemolytic anemia, with schistocytes in peripheral blood, was present, as well as a persistent low platelet count and activity of von Willebrand factor from adherence to protease (ADAMTS-13) less than 1 %. The presence of IgG antibodies against ADAMTS-13 was documented, leading to a diagnosis of thrombotic thrombocytopenic purpura (TTP) in the context of Goodpasture's syndrome. The TTP was treated with rituximab and plasmapheresis with a good response. We conclude that early measurement of ADAMTS-13 activity dictated the most appropriate therapy and achieved excellent results in this patient.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23111709     DOI: 10.1007/s11255-012-0279-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  9 in total

1.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

2.  Thrombotic microangiopathy in a patient with anti-glomerular basement membrane antibody disease.

Authors:  Elizabeth Stallworthy; Maha Yehia
Journal:  Nephrology (Carlton)       Date:  2006-08       Impact factor: 2.506

3.  Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.

Authors:  Fadi Fakhouri; Jean-Paul Vernant; Agnès Veyradier; Martine Wolf; Gilles Kaplanski; Raynald Binaut; Manfred Rieger; Friedrich Scheiflinger; Pascale Poullin; Benjamin Deroure; Richard Delarue; Philippe Lesavre; Philippe Vanhille; Olivier Hermine; Giuseppe Remuzzi; Jean-Pierre Grünfeld
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

4.  Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

Authors:  Marie Scully; Hannah Cohen; Jamie Cavenagh; Sylvia Benjamin; Richard Starke; Sally Killick; Ian Mackie; Samuel J Machin
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

5.  [Rituximab provided long-term remission in a patient with severe thrombotic thrombocytopenic purpura refractory to plasma exchange].

Authors:  Hyunsoo Hong; Yasutaka Aoyama; Ryousuke Yamamura; Tadanobu Ohta; Atsuko Mugitani; Takahisa Yamane; Masayuki Hino; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Rinsho Ketsueki       Date:  2006-12

6.  A case report of pulmonary-renal syndrome treated with continuous hemodiafiltration and hemodialysis.

Authors:  Yoshitaka Uji; Tomoharu Shimizu; Toyokazu Yoshioka; Hiroshi Yamamoto; Yoshihiro Endo; Toru Tani
Journal:  Ther Apher Dial       Date:  2006-10       Impact factor: 1.762

7.  Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).

Authors:  Afaq Ahmad; Anita Aggarwal; Daya Sharma; Harish P Dave; Virginia Kinsella; Margaret E Rick; Geraldine P Schechter
Journal:  Am J Hematol       Date:  2004-10       Impact factor: 10.047

8.  ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.

Authors:  Manfred Rieger; Pier Mannuccio Mannucci; Johanna A Kremer Hovinga; Andrea Herzog; Gabi Gerstenbauer; Christian Konetschny; Klaus Zimmermann; Inge Scharrer; Flora Peyvandi; Miriam Galbusera; Giuseppe Remuzzi; Martina Böhm; Barbara Plaimauer; Bernhard Lämmle; Friedrich Scheiflinger
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

9.  Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; AnnCharlotte Kristoffersson; Reinhard Schneppenheim; Moin A Saleem; Peter W Mathieson; Matthias Mörgelin; Peter Björk; Lars Holmberg; Diana Karpman
Journal:  Br J Haematol       Date:  2007-07-12       Impact factor: 6.998

  9 in total
  2 in total

Review 1.  Rituximab in treatment of anti-GBM antibody glomerulonephritis: A case report and literature review.

Authors:  Mayu Uematsu-Uchida; Takehiro Ohira; Shigeki Tomita; Hiroshi Satonaka; Akihiro Tojo; Toshihiko Ishimitsu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

2.  A Case of Paediatric Anti-Glomerular Basement Membrane Disease Associated with Thrombotic Thrombocytopenic Purpura.

Authors:  Joseph McAllister; Pradeep Nagisetty; Kay Tyerman
Journal:  Case Rep Nephrol       Date:  2022-08-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.